A share price of Bicycle Therapeutics Plc ADR [BCYC] is currently trading at $7.35, up 1.80%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BCYC shares have lost -2.78% over the last week, with a monthly amount drifted -4.30%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] stock has seen the most recent analyst activity on November 08, 2024, when Stephens initiated its Equal-Weight rating and assigned the stock a price target of $25. Previously, RBC Capital Mkts started tracking the stock with Outperform rating on September 06, 2024, and set its price target to $35. On August 07, 2024, downgrade downgraded it’s rating to Neutral and revised its price target to $28 on the stock. B. Riley Securities upgraded its rating to a Buy. Cowen initiated its recommendation with a Outperform. Barclays started tracking with a Overweight rating for this stock on July 28, 2022, and assigned it a price target of $30.
Bicycle Therapeutics Plc ADR experienced fluctuations in its stock price throughout the past year between $6.10 and $28.67. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Bicycle Therapeutics Plc ADR [NASDAQ: BCYC] shares were valued at $7.35 at the most recent close of the market. An investor can expect a potential return of 199.32% based on the average BCYC price forecast.
Analyzing the BCYC fundamentals
Trailing Twelve Months sales for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] were 19.35M which represents -68.47% decline. Gross Profit Margin for this corporation currently stands at 0.78% with Operating Profit Margin at -9.94%, Pretax Profit Margin comes in at -8.4%, and Net Profit Margin reading is -7.9%. To continue investigating profitability, this company’s Return on Assets is posted at -0.23, Equity is -0.25 and Total Capital is -0.31. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 7.08 points at the first support level, and at 6.81 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.87, and for the 2nd resistance point, it is at 8.39.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Bicycle Therapeutics Plc ADR [NASDAQ:BCYC] is 10.39. In addition, the Quick Ratio stands at 10.39 and the Cash Ratio stands at 13.76. Considering the valuation of this stock, the price to sales ratio is 26.30, the price to book ratio is 0.76.
Transactions by insiders
Recent insider trading involved Lee Kevin, CHIEF EXECUTIVE OFFICER, that happened on Jul 03 ’25 when 3193.0 shares were sold. CHIEF EXECUTIVE OFFICER, Lee Kevin completed a deal on Jul 02 ’25 to sell 2268.0 shares. Meanwhile, CHIEF TECHNOLOGY OFFICER Skynner Michael sold 966.0 shares on Jul 03 ’25.
